Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2021

View Archived Issues

AstraZeneca patents SLC12A5 activators

Minghui Pharmaceutical scientists synthesize new JAK inhibitors

Evotec presents ISR pathway modulators

MCT4 is a prognostic marker in anaplastic thyroid cancer

Merck KGaA and Ryvu Therapeutics divulge new ACSS2 inhibitors

Sichuan Haisco Pharmaceutical describes new JAK inhibitors

SG-3-00802 shows encouraging preclinical activity in combination with anti-PD-1 therapy

HC-070 attenuates stress-related excessive sensitivity to aversion and apathy for reward in mice

Stealth's SBT-272 shows promise in murine model of ALS

Development of cell-penetrating asymmetric siRNAs for treating androgenetic alopecia

NK-92 with truncated PD-1 shows enhanced therapeutic effects

Dapiglutide attenuates intestinal insufficiency in vivo

Aileron Therapeutics' ALRN-6924 shows preclinical activity against acute radiation injury

Rare APOE variant gives insight into Alzheimer's pathogenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...